Deutsche Bank AG Has $2.73 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Deutsche Bank AG increased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 46.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 48,745 shares of the company’s stock after purchasing an additional 15,481 shares during the quarter. Deutsche Bank AG owned approximately 0.08% of Rhythm Pharmaceuticals worth $2,729,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. SRS Capital Advisors Inc. grew its stake in Rhythm Pharmaceuticals by 740.7% in the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock valued at $25,000 after buying an additional 400 shares during the last quarter. Raleigh Capital Management Inc. bought a new stake in Rhythm Pharmaceuticals in the 4th quarter valued at about $28,000. SBI Securities Co. Ltd. bought a new stake in Rhythm Pharmaceuticals in the 4th quarter valued at about $37,000. R Squared Ltd bought a new stake in Rhythm Pharmaceuticals in the 4th quarter valued at about $44,000. Finally, KBC Group NV boosted its holdings in Rhythm Pharmaceuticals by 78.2% in the 4th quarter. KBC Group NV now owns 2,251 shares of the company’s stock valued at $126,000 after purchasing an additional 988 shares during the period.

Rhythm Pharmaceuticals Stock Performance

Shares of NASDAQ:RYTM opened at $62.41 on Thursday. Rhythm Pharmaceuticals, Inc. has a 52-week low of $35.17 and a 52-week high of $68.58. The company has a fifty day moving average of $58.43 and a 200-day moving average of $57.60. The company has a market capitalization of $3.97 billion, a PE ratio of -14.41 and a beta of 2.36.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.12). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The firm had revenue of $37.72 million for the quarter, compared to analyst estimates of $40.43 million. During the same quarter last year, the company earned ($2.35) earnings per share. The company’s quarterly revenue was up 25.9% compared to the same quarter last year. On average, equities analysts forecast that Rhythm Pharmaceuticals, Inc. will post -4.32 EPS for the current fiscal year.

Insider Transactions at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, insider Pamela J. Cramer sold 7,031 shares of the firm’s stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $65.09, for a total value of $457,647.79. Following the transaction, the insider now directly owns 19,209 shares of the company’s stock, valued at approximately $1,250,313.81. This trade represents a 26.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Yann Mazabraud sold 75,000 shares of the firm’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the completion of the transaction, the executive vice president now directly owns 40,370 shares in the company, valued at $2,078,247.60. This trade represents a 65.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 127,630 shares of company stock worth $7,107,346 over the last three months. 6.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

RYTM has been the subject of a number of recent research reports. Canaccord Genuity Group boosted their price objective on shares of Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the company a “buy” rating in a report on Tuesday, April 8th. Wells Fargo & Company upped their price target on shares of Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the stock an “overweight” rating in a report on Monday, April 7th. Stifel Nicolaus assumed coverage on shares of Rhythm Pharmaceuticals in a report on Wednesday, March 5th. They set a “buy” rating and a $78.00 price target for the company. Morgan Stanley reaffirmed an “overweight” rating and set a $72.00 price target on shares of Rhythm Pharmaceuticals in a report on Friday, March 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target (up previously from $70.00) on shares of Rhythm Pharmaceuticals in a report on Tuesday, April 8th. Thirteen research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Rhythm Pharmaceuticals currently has an average rating of “Buy” and an average price target of $75.38.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.